Atrial fibrillation subtypes, risk of stroke, and antithrombotic therapy

European Heart Journal

Volumn 29, Issue 7, 2008, Pages 840-842

  Stramba Badiale, Marco ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; IRBESARTAN; WARFARIN;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; EDITORIAL; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; RISK FACTORS; STROKE;

EID: 41849136104     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm594     Document Type: Editorial

References (15)

1. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, Jonsson B, Schenck-Gustafsson K, Tendera M. Cardiovascular diseases in women: a statement from the policy conference of the European society of Cardiology. Eur Heart J 2006;27:994-1005.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-9878.
3. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987;1:526-529.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987; 147:1561-1564.
5. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2,012 participants in the SPAF I-III clinical trials. Stroke 1999;30:1223-1229.
6. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. 1. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
7. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Lévy S, Cobbe S, Kremastinos DT, Breithardt G, Cokkinos DV, Crijns HJGM. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007;49:572-577.
8. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL, for the Stroke prevention in atrial fibrillation investigators. Pathophysiologic correlates of thromboembolism in nonvavular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999;12:1080-1087.
9. Illien S, Maroto-Jarvinen S, von der Recke G, Hammerstingl C, Schmidt H, Kuntz-Hehner S, Luderitz B, Omran H. Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism. Heart 2003; 89:165-168.
10. Hart RG, Pearce LA, Aguilar MI. A meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
11. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, Lip GYH, Crijns HJGM, on behalf of the Euro Heart Survey Investigators. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008;29:915-922. First published on March 10, 2008. doi:10.1093/eurheartj/ehn101.
12. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, Connolly SJ for the ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-2161.
13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
14. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030.
15. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SFS, May HT, Samuelson KM, Muhlestein JB, Carlquist JF for the Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116:2563-2570.